Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 6

The Rationale for PARP Inhibition plus IO in Ovarian Cancer

, , ,

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

EP. 1: Recent Updates in PARP Inhibitor Indications for Ovarian Cancer
EP. 2: PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial
EP. 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer
EP. 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial
EP. 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial
Now Viewing
EP. 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer
EP. 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment
EP. 8: PARP Inhibitor Resistance in Ovarian Cancer Treatment
EP. 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer
EP. 10: Antibody-Drug Conjugates in Ovarian Cancer Treatment
EP. 11: Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer
EP. 12: Investigative Therapies in Recurrent Ovarian Cancer
EP. 13: Treatment of Rare Tumors in Ovarian Cancer
EP. 14: Key Data Highlights in Ovarian Cancer

Related Content:

Optimizing Therapy for Ovarian Cancer: Recent Data HighlightsOvarian CancerOncLive Peer Exchange®
Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
OncLive’s June Roundup of Key FDA Approvals in Oncology
FDA Grants Fast Track Designation to Radspherin for Peritoneal Carcinomatosis From Ovarian Cancer